Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-12-27Clinical Trial Update: Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue [Phase 4]
Phase 4 clinical trial evaluating cognitive behavioral therapy, modafinil, or both for fatigue in people with multiple sclerosis; completed …
-
CLINICAL_TRIALS trial_result · 2022-12-21Clinical Trial Update: Transcranial Direct Current Stimulation and Walking in Multiple Sclerosis [NA]
Clinical trial update on transcranial direct current stimulation and walking in multiple sclerosis; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-12-12Clinical Trial Update: Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis [Phase 4]
Phase 4 trial update examining teriflunomide concentration in serum and cerebrospinal fluid of patients with multiple sclerosis.
-
FDA approval · 2022-12-09FDA Approved: TASCENSO ODT — Original Application (Cycle Pharmaceuticals Ltd)
The FDA approved TASCENSO ODT, an oral disintegrating tablet containing fingolimod lauryl sulfate, under an original application by Cycle Ph…
-
CLINICAL_TRIALS trial_result · 2022-11-29Clinical Trial Update: Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis [NA]
A terminated clinical trial evaluating transcranial direct current stimulation for reducing neuropathic pain in people with multiple scleros…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-11-18Clinical Trial Update: Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS [NA]
A terminated clinical trial evaluating activity and balanced eating to reduce comorbidities and symptoms in people with multiple sclerosis; …
-
FDA approval · 2022-11-16FDA Approved: VUMERITY — Supplemental Application (Biogen Inc.)
FDA approved Biogen's supplemental application for VUMERITY (diroximel fumarate).
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS [Phase 2]
Phase 2 trial assessing repeated administration of NurOwn (MSC-NTF cells) for progressive multiple sclerosis; results posted after completio…
-
FDA approval · 2022-11-02FDA Approved: TERIFLUNOMIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for the generic Teriflunomide from Aurobindo Pharma Limited under an ANDA. This allows the produ…
-
FDA approval · 2022-11-01FDA Approved: TERIFLUNOMIDE — Supplemental Application (MSN LABORATORIES PRIVATE LIMITED)
FDA approved a supplemental application for teriflunomide submitted by MSN Laboratories Private Limited. This action expands the regulatory …
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: FMT for MS Patients [Phase 2]
Phase 2 clinical trial update for fecal microbiota transplantation in multiple sclerosis patients; status information is currently unknown.
-
CLINICAL_TRIALS trial_result · 2022-10-20Clinical Trial Update: MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV [Phase 4]
Phase 4 clinical trial update for the MAIN STUDY: SWITCH sub-study SWITCH-JCV in multiple sclerosis has completed with results posted in 202…
-
CLINICAL_TRIALS trial_result · 2022-10-18Clinical Trial Update: Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis [Phase 3]
Phase 3 trial update for Xacrel (Ocrelizumab) in relapsing-remitting multiple sclerosis reports efficacy and safety data.
-
FDA approval · 2022-10-18FDA Approved: DIMETHYL FUMARATE — Original Application (Solco Healthcare US, LLC)
The FDA approved the original application for a generic Dimethyl Fumarate manufactured by Solco Healthcare US, LLC. Dimethyl Fumarate is use…
-
FDA approval · 2022-10-07FDA Approved: TERIFLUNOMIDE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' supplemental application for teriflunomide, granting approval of a generic product for the treatment o…
-
CLINICAL_TRIALS trial_result · 2022-10-06Clinical Trial Update: Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) [Phase 4]
Phase 4 trial update on discontinuation of disease-modifying therapies (DMTs) in multiple sclerosis, with results posted after completion.
-
FDA approval · 2022-09-29FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
FDA approved a supplemental application for Tecfidera (dimethyl fumarate) submitted by Biogen Inc., resulting in updated labeling.
-
FDA approval · 2022-09-29FDA Approved: VUMERITY — Supplemental Application (Biogen Inc.)
The FDA approved Biogen's supplemental application for VUMERITY (diroximel fumarate), indicating an approved modification to its labeling/in…
-
FDA approval · 2022-09-29FDA Approved: ZEPOSIA 7-DAY STARTER PACK — Supplemental Application (Celgene Corporation)
FDA supplemental application approval to offer a Zeposia 7-day starter pack (ozanimod hydrochloride) for initiation of therapy.
-
FDA approval · 2022-09-21FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for GLATOPA, a generic glatiramer acetate product from Sandoz Inc.
-
FDA approval · 2022-09-21FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for GLATOPA (glatiramer acetate) from Sandoz Inc, a generic version of glatiramer acetate.
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: Vaginal Estriol in Multiple Sclerosis [Phase 2, Phase 3]
A completed Phase 2/3 clinical trial evaluating vaginal estriol for multiple sclerosis and neurogenic bladder has results posted.
-
FDA approval · 2022-09-19FDA Approved: MAVENCLAD — Supplemental Application (EMD Serono, Inc.)
The FDA approved a supplemental application for Mavenclad (cladribine) submitted by EMD Serono, Inc.
-
CLINICAL_TRIALS trial_result · 2022-09-16Clinical Trial Update: Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis [Phase 2]
Phase 2 clinical trial evaluating lisdexamfetamine sulfate for cognitive dysfunction in multiple sclerosis has completed with results posted…
-
CLINICAL_TRIALS trial_result · 2022-09-14Clinical Trial Update: CPAP to Treat Cognitive Dysfunction in MS [NA]
Clinical trial investigating CPAP treatment for cognitive dysfunction in multiple sclerosis has completed, with results posted in 2022.